Positive quarter from Takeda, waiting for completion of Shire deal

Takeda yesterday announced to the financial community its last six months’ results (Japanese calendar). Sales rose 4.2%, especially thanks to the assets that Takeda itself refers to as “growth drivers”–Gastroenterology, Oncology, Neuroscience and Emerging Markets divisions, which have increased by 9.8%.  The market data are so positive that the management has improved the current-year guidance by 36%, with profits expected to reach JYN189.5bn ($1.7bn), which will make the Japan-based group one of the pharma sector giants. Takeda is simultaneously seeking to fund Shire’s acquisition, paid GBP46bn, which will grant the Japan-based group access to a rich portfolio of rare disease treatments. Takeda’s shares  rose an impressive 5% (Tokyo) soon after the results were announced, increasing the company’s capitalization to almost JYN4000bn.